Search
Atopic Dermatitis Clinical Trials
A listing of 58 Atopic Dermatitis clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 12 of 58
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Atopic Dermatitis
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
There are currently 58 active clinical trials seeking participants for Atopic Dermatitis research studies. The states with the highest number of trials for Atopic Dermatitis participants are California, Florida, Texas and Ontario.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Atopic Dermatitis Study
Recruiting
The BroADen Study is looking for adults 18–55 to join in on research for a once-daily oral study drug that
may help reduce the symptoms of atopic dermatitis (AD). This research is evaluating if the investigational
study drug is safe and how it works in adults with moderate to severe AD (eczema).
may help reduce the symptoms of atopic dermatitis (AD). This research is evaluating if the investigational
study drug is safe and how it works in adults with moderate to severe AD (eczema).
Conditions:
Atopic Dermatitis
Dermatitis
Atopic
Atopic Dermatitis Eczema
Moderate-to-Severe Atopic Dermatitis
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
Recruiting
This is a multicenter, double-blind, Long-Term Extension (LTE) study to evaluate the long-term safety and efficacy of APG777 in patients with moderate-to-severe AD who have completed treatment in an APG777 Parent Study (NCT06395948).
The LTE study will consist of 3 periods: 1) Screening Visit will coincide with the last visit of the Maintenance Period in the Parent Study 2) Extended Treatment Period 3) Post-treatment Follow-up Period.
This study will be conducted in participants with atopic de... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: Investigational Site #25, Fountain Valley, California +31 locations
Conditions: Atopic Dermatitis
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
Recruiting
The purpose of this study is to evaluate the efficacy and safety of different dose regimens of IMG-007, compared to placebo.
Gender:
ALL
Ages:
Between 18 years and 74 years
Trial Updated:
07/25/2025
Locations: Antelope Valley Clinical Trials, Lancaster, California +3 locations
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
Recruiting
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment. This study aims to provide data on the efficacy and safety of upadacitinib at different doses in adult participants with moderate to severe AD.
Upadacitinib is an approved drug for the treatment of moderate to severe atopic dermatitis (AD). This stud... Read More
Gender:
ALL
Ages:
Between 18 years and 63 years
Trial Updated:
07/24/2025
Locations: Clinical Trials Institute - Northwest Arkansas /ID# 267290, Fayetteville, Arkansas +95 locations
Conditions: Atopic Dermatitis
A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
Recruiting
The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.
Gender:
ALL
Ages:
Between 12 years and 100 years
Trial Updated:
07/24/2025
Locations: Cahaba Dermatology and Skin Health Center, Birmingham, Alabama +539 locations
Conditions: Atopic Dermatitis
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis
Recruiting
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. The purpose of this study is to evaluate the clinical efficacy and safety of single therapies and/or combination therapies for moderate to severe AD through multiple substudies.
This study will consist of multiple sub-studies, Sub-Study 1 will have a randomized, placebo controlled period 1 followed by a lutikizumab treatment period 2 enrolling 80 participants at a 1 to 1 ratio.
In Sub-... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2025
Locations: Peak Dermatology Aesthetics and Wellness Fountain Hills /ID# 272550, Fountain Hills, Arizona +24 locations
Conditions: Atopic Dermatitis
A Study Evaluating APG777 in Atopic Dermatitis
Recruiting
This is a two-part study that will evaluate the safety and efficacy of APG777 in participants with moderate-to-severe Atopic Dermatitis (AD). Part A (Proof-of-concept) and Part B (Dose-regimen Finding) will evaluate the safety and efficacy of various induction and maintenance dose regimens of APG777 compared to placebo. The study duration for any individual participant will be up to 106 weeks which includes: screening, induction, maintenance, and post-treatment follow-up periods. Participants ra... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2025
Locations: Investigational Site #14, Fountain Valley, California +87 locations
Conditions: Atopic Dermatitis
Lebrikizumab in Moderate-to-severe Atopic Dermatitis
Recruiting
This research is studying a drug already approved for the treatment of atopic dermatitis (AD). This research collects health-related information and blood and skin samples to understand if the study drug, lebrikizumab, leads to long-term improvement in AD skin.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: Physioseq USA - CA, Folsom, California +3 locations
Conditions: Atopic Dermatitis
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
Recruiting
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Topical therapies applied over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment. This study compares upadacitinib to dupilumab in pediatric participants with moderate to severe AD who are candidates for systemic therapy. Adverse events and change in the disease activity will be assessed.
Upadacitinib is an approved drug... Read More
Gender:
ALL
Ages:
Between 2 years and 11 years
Trial Updated:
07/21/2025
Locations: Applied Research Center Of Arkansas /ID# 268547, Little Rock, Arkansas +132 locations
Conditions: Atopic Dermatitis
Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD
Recruiting
Safety, tolerability, and preliminary efficacy of soquelitinib in participants with moderate to severe AD
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2025
Locations: Clinical Site 5, Birmingham, Alabama +15 locations
Conditions: Atopic Dermatitis
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
Recruiting
The purpose of this study is to assess the efficacy and safety of Afimkibart (also known as RO7790121) in participants with moderate to severe atopic dermatitis (AD).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: Dermatology Research Associate, Los Angeles, California +24 locations
Conditions: Atopic Dermatitis
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis
Recruiting
The purpose of the study is to assess the efficacy and safety of ruxolitinib cream in children and adolescents (6 to \<18 Years Old) with moderate atopic dermatitis.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
07/15/2025
Locations: Clinical Research Center of Alabama, Birmingham, Alabama +92 locations
Conditions: Atopic Dermatitis
Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
Recruiting
The main aim of the study is to assess real-world effectiveness of nemolizumab in Atopic Dermatitis (AD) as measured by physician assessment and patient reported outcome (PRO) in clinical practice at Month 6.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/15/2025
Locations: Galderma Investigational Site - 8893, Birmingham, Alabama +110 locations
Conditions: Atopic Dermatitis
1 - 12 of 58